Veozah vs. Lynkuet for Menopause Hot Flashes and Sleep
Veozah (fezolinetant) and Lynkuet (elinzanetant) are both non-hormonal prescription pills that reduce hot flashes by a similar amount in trials. Lynkuet also has published evidence that part of its sleep benefit is independent of hot-flash relief; Veozah's isn't shown to work that way. Veozah carries a Boxed Warning for rare liver injury; Lynkuet's liver monitoring is lighter.
I hadn't planned to write about either of these drugs yet. Both felt too new, too unproven-in-the-real-world, to say anything useful about beyond repeating the press release. Then a reader emailed asking, flatly, "which one" — her doctor had mentioned both in the same breath and she wanted to know what actually separated them before her next appointment.
That's a fair question, and it turns out the honest answer isn't obvious. Coverage of both drugs tends to collapse them into "the new non-hormonal hot flash pills," as if they're interchangeable. Reading the actual trial data and FDA labeling, they aren't — not in how they might affect sleep, and not in how closely you'd need to be monitored while taking either one.
If you haven't read our piece on gabapentin for menopause hot flashes, that's the older, cheaper, off-label non-hormonal option these two new drugs are effectively competing with. This article is about the two newest, purpose-built entrants specifically.
The honest framing up front: both drugs work, roughly comparably, on hot flash frequency. The differences that actually matter for a sleep-focused decision are in the sleep-specific evidence and the safety monitoring — and those two things point in somewhat different directions for each drug.
What are Veozah and Lynkuet, and how are they different?
Both are neurokinin (NK) receptor antagonists — a drug class that targets the brain circuit regulating body temperature, which goes haywire during menopause as estrogen drops. Veozah (fezolinetant, Astellas) blocks a single receptor, NK3, approved by the FDA in May 2023. Lynkuet (elinzanetant, Bayer) blocks two receptors, NK1 and NK3, approved in October 2025.
Neither is hormonal, so neither carries the blood clot or breast cancer considerations that come with estrogen-based hormone therapy. Both require a prescription and neither is available over the counter or through the kind of affiliate-linkable supplement store most of the rest of this site covers — these are drugs, prescribed and monitored by a doctor, not products you compare and buy.
Do they actually help you sleep, or just reduce hot flashes?
Both improved self-reported sleep in their trials, which sounds like the same answer twice. It isn't quite. The more interesting and more recent evidence, specific to elinzanetant, suggests its sleep benefit is only partly explained by fewer night sweats. Fezolinetant's own manufacturer describes its sleep improvement as a downstream effect of calmer nights, not a separate mechanism.
That distinction sounds like a technicality, but it matters if hot flashes aren't your only sleep problem. A drug that helps sleep only by quieting hot flashes won't do much for the nights you're awake for other reasons; a drug with even a partly independent sleep effect has a plausible reason to help beyond that.
What does the elinzanetant (Lynkuet) sleep evidence show specifically?
Lynkuet's approval rested on three phase 3 trials, OASIS 1, 2, and 3, published in JAMA in 2024. Alongside reducing hot flash frequency, elinzanetant significantly improved a validated sleep-disturbance score and menopause-specific quality of life as secondary endpoints — not just a side note buried in the safety tables.
That's a genuinely distinctive claim for this drug class: over half the sleep benefit showing up on a formal statistical test as separate from the hot-flash effect. One plausible explanation researchers point to is that the NK1 receptor — the one elinzanetant blocks that fezolinetant doesn't — has its own role in stress and arousal circuits unrelated to body temperature, though that mechanism isn't fully proven.
What does the fezolinetant (Veozah) sleep evidence show?
Veozah's sleep data comes from a pooled analysis of the SKYLIGHT 1 and 2 trials, published in Maturitas in 2024, and it's real: sleep-disturbance scores improved by week 4 and held through week 12. What's missing, at least in what's been published so far, is a mediation analysis like elinzanetant's that separates a direct sleep effect from an indirect one.
Astellas's own patient materials are explicit about the mechanism they believe is at work: fezolinetant improves sleep "by addressing the underlying cause of VMS and night sweats, without inducing sleep." In plain terms, the company's own framing is that it works on sleep by working on hot flashes first — not through a separate pathway.
That's not a knock on fezolinetant. Reducing the number of times you wake up drenched and overheated is a completely legitimate route to better sleep, and it's the one older non-hormonal options like gabapentin work through too. It's simply a different, less novel claim than "improves sleep independent of hot flashes," which is the more unusual finding attached to elinzanetant so far.
How do their liver safety profiles compare?
This is where the two drugs diverge most clearly on paper. In September 2024, the FDA added a Boxed Warning — its most serious category of warning — to Veozah, after rare postmarketing reports of serious liver injury. Lynkuet, approved over a year later, carries liver monitoring guidance but no Boxed Warning.
Read that carefully and the picture is more nuanced than "one is dangerous, one is safe." Veozah's warning followed real-world reports after millions of prescriptions, which is exactly the kind of rare signal a smaller pre-approval trial can miss. Lynkuet simply hasn't been on the market long enough to have generated that same volume of postmarketing surveillance yet — its current, lighter monitoring reflects what trials showed, not necessarily the final word.
Neither drug should be started with active liver disease, and both require baseline liver bloodwork before your first dose. Tell your prescriber about any history of liver problems, and report new fatigue, nausea, yellowing skin or eyes, dark urine, or abdominal pain immediately if it comes up while you're on either one.
How do they compare to HRT or gabapentin?
For women who can safely take it, hormone therapy produces the most reliable improvement in hot-flash-driven sleep of any option here — see our honest look at HRT for menopause insomnia for who that is and isn't. Gabapentin, covered in our gabapentin article, has decades of real-world use, but its sedating side effect is a trade-off, not a feature.
| Veozah | Lynkuet | Gabapentin | |
|---|---|---|---|
| Hormonal? | No | No | No |
| Sleep effect independent of hot flashes? | Not shown | Yes, partly (54.3%) | Via sedation, not the same claim |
| Liver monitoring | Boxed Warning — monthly ×3, then 6 & 9 mo | Baseline + 3 months | Not a liver-monitored drug |
| How long on the market | Since May 2023 | Since Oct. 2025 | Decades (off-label use) |
None of these is automatically "best." A woman with a strong contraindication to hormones, real liver concerns, and hot flashes as her only sleep disruptor is a very different candidate than one whose sleep is fragmented for reasons hot flashes don't explain, where gabapentin's sedation or even a sleep-specific prescription might fit better.
Who's a good candidate, and who should skip these?
These are worth discussing with a doctor if hot flashes and night sweats are clearly driving your poor sleep, you can't or don't want to take hormone therapy, and you're able to commit to the liver-monitoring schedule. They're prescription-only for a reason — this isn't a supplement aisle decision.
- Possibly a good fit: hot-flash-driven sleep disruption, hormone therapy ruled out or declined, no personal or strong family history of liver disease, willing to do the required bloodwork
- Worth a longer conversation first: any history of elevated liver enzymes, liver disease, or heavy alcohol use; taking other medications that stress the liver
- Probably not the first move: sleep disruption that isn't clearly tied to hot flashes or night sweats — these drugs are built for vasomotor symptoms specifically, not insomnia broadly
What do they cost, and how do you get started?
Both are recent brand-name drugs without a generic option, so expect a real out-of-pocket cost if your insurance hasn't added them to its formulary — coverage varies by plan since both are still working through insurer approval. Ask the prescribing office about manufacturer copay or savings-card programs rather than assuming the sticker price online is what you'd pay.
Starting either one means a baseline conversation with your doctor about your liver history, baseline bloodwork, and a follow-up test scheduled before you fill the prescription — not after. Bring your two weeks of sleep and hot-flash tracking to that appointment if you have it; it's exactly the kind of detail that helps a doctor judge whether either drug is likely to move the needle for you specifically.
Where to go from here
For the established non-hormonal option these two are competing with, our gabapentin article covers the trade-offs of an older, cheaper, off-label drug. If hormone therapy is still on the table for you, our honest look at HRT for menopause insomnia is the most effective option most women haven't fully ruled out yet. And if hot flashes aren't your main issue at all, our guide to sleeping pills for menopause insomnia covers medications built for sleep itself.
For how everything fits together, start at the complete perimenopause and menopause sleep guide.
Key takeaways
- Veozah (fezolinetant, since 2023) and Lynkuet (elinzanetant, since Oct. 2025) are both non-hormonal prescription pills that reduce hot flashes by a similar amount in trials.
- A 2026 mediation analysis found 54.3% of elinzanetant's sleep benefit is independent of hot-flash reduction — a distinct sleep effect, not just calmer nights.
- Fezolinetant's sleep improvement is described by its own maker as working through reducing hot flashes and night sweats, not a separate mechanism.
- Veozah carries an FDA Boxed Warning for rare serious liver injury (added Sept. 2024) requiring monthly liver tests for 3 months, then at 6 and 9 months.
- Lynkuet's liver monitoring is lighter (baseline plus 3 months) and it has no Boxed Warning, though it's also newer, with less postmarketing data collected.
- Neither should be started with active liver disease, and both are prescription-only, requiring a doctor's monitoring throughout treatment.
- Hormone therapy remains the most effective option for hot-flash-driven insomnia for women who can take it safely; gabapentin remains the older, cheaper non-hormonal alternative.
- Both are new brand-name drugs — ask about cost and insurance coverage before assuming the online price is what you'll pay.
Frequently asked questions
Do Veozah and Lynkuet actually help you sleep, or just reduce hot flashes?
Both improved patient-reported sleep in their trials, but the evidence behind why differs. Lynkuet (elinzanetant) has a published analysis showing over half its sleep benefit happens independent of hot flash reduction. Veozah's (fezolinetant) maker describes its sleep benefit as working through reducing night sweats, not a separate sleep mechanism.
What's the real difference between fezolinetant and elinzanetant?
Fezolinetant (Veozah) blocks one brain receptor (NK3); elinzanetant (Lynkuet) blocks two (NK1 and NK3). Both cut hot flashes by a similar amount in trials. The practical differences are newer FDA safety data: Veozah carries a Boxed Warning for rare serious liver injury; Lynkuet's liver monitoring is lighter, with no Boxed Warning as of its 2025 approval.
Is the liver risk something to actually worry about?
For most people, no, but it's not nothing. Veozah's Boxed Warning followed rare postmarketing reports of serious injury, requiring liver tests monthly for 3 months, then at 6 and 9. Lynkuet's trials found transaminase elevations in 0.6% of users versus 0.4% on placebo, with one liver check at 3 months. Neither should start with active liver disease.
How do they compare to HRT or gabapentin for sleep?
Hormone therapy remains the most effective option for hot-flash-driven insomnia for women who can take it safely. Gabapentin has solid trial evidence but causes sedation and grogginess as a side effect, not a target. Veozah and Lynkuet sit in between: non-hormonal, prescription-only, and priced and monitored more like a new specialty drug than a sleep aid.
How much do they cost, and is insurance likely to cover them?
As new brand-name drugs, expect a real cost without insurance coverage, and coverage varies a lot by plan since both are still working through formulary approval at many insurers. Ask the prescribing office about manufacturer savings or copay programs before assuming the price you see online is what you'll actually pay.
How long before you know if one is working?
Trials measured hot flash frequency at 4 and 12 weeks, with the fuller effect visible by week 4 and continuing to build through week 12. Give it at least a month of consistent use, tracking hot flash count and sleep, before deciding it isn't the right fit for you.
Sources cited
- Lederman S, Santoro N, Simon JA, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024;332(16):1343-1354. pubmed.ncbi.nlm.nih.gov
- Elinzanetant Improves Sleep Disturbances Partly Independent of Nighttime Vasomotor Symptoms: Post-Hoc Mediation Analysis from Four Trials. Sleep. 2026;49(Suppl 1):A375. academic.oup.com
- Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401:1091-1102. pubmed.ncbi.nlm.nih.gov
- Shapiro CMM, Cano A, Nappi RE, et al. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause. Maturitas. 2024;186:107999. pubmed.ncbi.nlm.nih.gov
- U.S. Food and Drug Administration. FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause. Drug Safety Communication, Sept. 12, 2024 (updated Dec. 16, 2024). fda.gov
- LYNKUET (elinzanetant) Prescribing Information, Section 5.2 Hepatic Transaminase Elevations. DailyMed, U.S. National Library of Medicine, 2025. dailymed.nlm.nih.gov
Ellen Hayes
Health & Wellness Writer and Researcher
Hi — I'm Ellen. A reader's question sent me down this particular rabbit hole, and I came out of it glad I hadn't just repeated the "two new hot flash pills" headline. The liver monitoring difference alone felt like something worth actually reading the FDA paperwork for, rather than trusting a summary.
I'm not a doctor. I'm not an expert — and I'm never going to talk down to you like one. I'm a woman in the middle of perimenopause who got tired of vague answers, started reading the actual research, and writes it down here in plain English, the way I'd explain it to a friend over coffee. More about Ellen →